Evidence map›Paper›PMID 40418395›Full record

ArticleCancer chemotherapy and pharmacology2025

Pharmacokinetics, mass balance, and metabolism of [

Lei Gao, Sheng Ma, Shu Yan, Hua Zhang, Ling Tian, Lize Li, Lei Diao, Liyan Miao, Xiaoran Yang, Xingxing Diao

Abstract read
PubMed Publisher
In one paragraph

Article in Cancer chemotherapy and pharmacology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed.

  1. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

10 authors.

Lei Gao *Shanghai Institute of Materia Medica, Chinese Academy of Sciences, Shanghai, 201210, China.
Sheng Ma *First Affiliated Hospital of Soochow University, Jiangsu, 215006, China.
Shu YanShanghai Institute of Materia Medica, Chinese Academy of Sciences, Shanghai, 201210, China.
Hua ZhangFirst Affiliated Hospital of Soochow University, Jiangsu, 215006, China.
Ling TianLiaoning Avanc Pharmaceutical Co., Ltd., Liaoning, 121013, China.
Lize LiLiaoning Avanc Pharmaceutical Co., Ltd., Liaoning, 121013, China.
Lei DiaoShanghai Fosun Pharmaceutical (Group) Co., Ltd, Shanghai, 200233, China.
Liyan MiaoFirst Affiliated Hospital of Soochow University, Jiangsu, 215006, China. miaolysuzhou@163.com.
Xiaoran YangLiaoning Avanc Pharmaceutical Co., Ltd., Liaoning, 121013, China. yangxiaoran@avancpharma.com.
Xingxing DiaoShanghai Institute of Materia Medica, Chinese Academy of Sciences, Shanghai, 201210, China. xxdiao@simm.ac.cn.

Funding

Key Technologies R&D Program of Guangdong Province 2023B1111030004National Key Research and Development Program of China 2022YFF1202600National Natural Science Foundation of China 82373938
6 · The paper itself

Abstract

This study investigated the pharmacokinetics, mass balance, and metabolism of [

Indexed as

Cyclin-Dependent Kinase 4Cyclin-Dependent Kinase 6Protein Kinase InhibitorsAdministration, OralAdultCarbon RadioisotopesFecesHumansMaleOrganic ChemicalsYoung AdultCarbon RadioisotopesCDK4 protein, humanCDK6 protein, humanCyclin-Dependent Kinase 4Cyclin-Dependent Kinase 6FCN-437cOrganic ChemicalsProtein Kinase InhibitorsCDK4/6 inhibitorDrug metabolismFCN-437cMass balanceRadiopharmacokinetics

Identifiers

PMID40418395

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.